Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as placulumab
CEP-37247 · 1 trial · 1 indication
The average pain intensity over the past 24 hours on the NRS-11 will be collected daily by electronic diary.
| Arm | Type | Description |
|---|---|---|
| CEP-37247 | EXPERIMENTAL | - |
| Matching placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CEP-37247 | DRUG | 0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route. |
| Placebo | DRUG | Matching placebo vials will be filled with the buffered solution for CEP-37247. |
Inclusion Criteria: * Over the 4 days prior to the randomization visit, the patient has a mean score greater than or equal to 5 (of 10) for "Average Pain Over the Past 24 Hours" for the pain in the affected leg as assessed by the 11-Point Numerical Rating Scale (NRS-11) captured in the electronic d...
CEP-37247 is an investigational small molecule developed by Teva Pharmaceutical Industries Limited for sciatica, specifically lumbosacral radicular pain associated with disk herniation. It was studied as a transforaminal epidural treatment. CEP-37247 is also known as placulumab.
CEP-37247 was developed for the treatment of sciatica, described in its trial as lumbosacral radicular pain associated with disk herniation. It was administered by the transforaminal epidural route. The program is in the pain therapeutic area.
CEP-37247 is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva sponsored the clinical study of the drug in sciatica.
CEP-37247 is in Phase 1 development. It is investigational and has not been approved. The single Phase 1 trial has been completed, and no trials are currently active.
CEP-37247 was studied in one Phase 1 trial, NCT01240876, titled a study to evaluate the safety and efficacy of placulumab (CEP-37247) administered by the transforaminal epidural route in patients with lumbosacral radicular pain associated with disk herniation. The trial enrolled 98 patients in the United States and Australia and is completed.
Yes, CEP-37247 is also known as placulumab. The two names refer to the same investigational drug, which Teva Pharmaceutical Industries Limited studied in a Phase 1 trial for sciatica.